Tieteelliset julkaisut

Tulokset kategoriasta menetelmat hakusanalla asiantuntijalausunto. Takaisin


European rating of drug harms. (van Amsterdam J, Nutt D, Phillips L, van den Brink W, 2015)
Julkaisu:Journal of Psychopharmacology
Tiivistelmä: BACKGROUND:
The present paper describes the results of a rating study performed by a group of European Union (EU) drug experts using the multi-criteria decision analysis model for evaluating drug harms.

METHODS:
Forty drug experts from throughout the EU scored 20 drugs on 16 harm criteria. The expert group also assessed criteria weights that would apply, on average, across the EU. Weighted averages of the scores provided a single, overall weighted harm score (range: 0-100) for each drug.

RESULTS:
Alcohol, heroin and crack emerged as the most harmful drugs (overall weighted harm score 72, 55 and 50, respectively). The remaining drugs had an overall weighted harm score of 38 or less, making them much less harmful than alcohol. The overall weighted harm scores of the EU experts correlated well with those previously given by the UK panel.

CONCLUSION:
The outcome of this study shows that the previous national rankings based on the relative harms of different drugs are endorsed throughout the EU. The results indicates that EU and national drug policy measures should focus on drugs with the highest overall harm, including alcohol and tobacco, whereas drugs such as cannabis and ecstasy should be given lower priority including a lower legal classification.
Yhdiste:päihteet yleisesti, LSD, psilosybiini, MDMA
Aihe:haitta-arvio
Menetelmät:Kirjallisuuskatsaus, asiantuntijalausunto
Otoskoko:0
Muuta:
Tagit: alkoholi, haitallisuusarvio, päihteet, tupakka
DOI:10.1177/0269881115581980
URL: http://journals.sagepub.com/doi/abs/10.1177/0269881115581980


The potential dangers of using MDMA for psychotherapy. (Parrott AC, 2014)
Julkaisu:Journal of Psychoactive Drugs
Tiivistelmä: MDMA has properties that may make it attractive for psychotherapy, although many of its effects are potentially problematic. These contrasting effects will be critically reviewed in order to assess whether MDMA could be safe for clinical usage. Early studies from the 1980s noted that MDMA was an entactogen, engendering feelings of love and warmth. However, negative experiences can also occur with MDMA since it is not selective in the thoughts or emotions it releases. This unpredictability in the psychological material released is similar to another serotonergic drug, LSD. Acute MDMA has powerful neurohormonal effects, increasing cortisol, oxytocin, testosterone, and other hormone levels. The release of oxytocin may facilitate psychotherapy, whereas cortisol may increase stress and be counterproductive. MDMA administration is followed by a period of neurochemical recovery, when low serotonin levels are often accompanied by lethargy and depression. Regular usage can also lead to serotonergic neurotoxicity, memory problems, and other psychobiological problems. Proponents of MDMA-assisted therapy state that it should only be used for reactive disorders (such as PTSD) since it can exacerbate distress in those with a prior psychiatric history. Overall, many issues need to be considered when debating the relative benefits and dangers of using MDMA for psychotherapy.
Yhdiste:MDMA
Aihe:Yleiset vaikutukset, haitta-arvio
Menetelmät:Kirjallisuuskatsaus, asiantuntijalausunto
Otoskoko:0
Muuta:
Tagit:
DOI:10.1080/02791072.2014.873690
URL: https://www.ncbi.nlm.nih.gov/pubmed/24830184


Human hallucinogen research: guidelines for safety. (Johnson M, Richards W, Griffiths R, 2008)
Julkaisu:Journal of Psychopharmacology
Tiivistelmä: There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks.

Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their administration involves unique psychological risks. The most likely risk is overwhelming distress during drug action ('bad trip'), which could lead to potentially dangerous behaviour such as leaving the study site. Less common are prolonged psychoses triggered by hallucinogens.

Safeguards against these risks include the exclusion of volunteers with personal or family history of psychotic disorders or other severe psychiatric disorders, establishing trust and rapport between session monitors and volunteer before the session, careful volunteer preparation, a safe physical session environment and interpersonal support from at least two study monitors during the session. Investigators should probe for the relatively rare hallucinogen persisting perception disorder in follow-up contact.

Persisting adverse reactions are rare when research is conducted along these guidelines. Incautious research may jeopardize participant safety and future research. However, carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.
Yhdiste:Psykedeelit yleisesti, LSD, psilosybiini
Aihe:Haitta-arvio
Menetelmät:Kirjallisuuskatsaus, asiantuntijalausunto
Otoskoko:0
Muuta:
Tagit:
DOI:10.1177/0269881108093587
URL: http://journals.sagepub.com/doi/abs/10.1177/0269881108093587